



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BIOMARK’S Clinical Technology Center at Innovation Boulevard in Surrey BC

Vancouver, British Columbia – (April 27, 2015) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) is pleased to announce that it will be setting up an office at the “Health Technology Innovation Hub” located at 13737 96th Avenue, Surrey, BC starting May 1st 2015.

President and CEO of BioMark, Rashid Ahmed says: “This new office will be the Canadian clinical technology gateway center for BioMark as we develop and prime technologies for commercialization. The facilities, environment and location are an ideal convergence for technology development and testing. Accesses to physicians, researchers, instruments and active support from the Health Tech Innovation Foundation allow BioMark to practically accelerate our test, design and introduce medical technologies and solutions in an ideal setting. The facilities and site provides BioMark the perfect ecosystem to accelerate our technology development at point of care while leveraging the excellent resources available within this dynamic “hub”.”

About Innovation Boulevard

Innovation Boulevard is an area consisting of 1 square mile in Surrey City Centre encompassing Surrey Memorial Hospital - Simon Fraser University - 3 other Academic institutions - 9 Technology Test beds and over 188 medical related businesses. Innovation Boulevard is an agile partnership of health, business, higher education and government creating new health technologies to improve peoples' lives. Its focus is on 3 technology areas: medical devices, independent living and digital health. Innovation Boulevard’s shared vision is to achieve remarkable results in 4 areas:

1. Improve health outcomes.
2. Implement intelligent solutions for the health care system.
3. Attract talented clinicians and researchers.
4. Grow companies in health care technology and services sectors.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer, early and cost effectively. BioMark is currently conducting Phase 3 multi site clinical trial for lung, breast, gastro intestinal and prostate cancers. Additionally trials related to assess response to lung cancer treatment and surgical interventions are being established.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.

For further information on BioMark, please Contact:

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

Tel. 604-282-6567

Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.

The CSE has not reviewed, approved or disapproved the content of this press release.